Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Unknown 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1131Neoplasms 986Carcinoma, Non-Small-Cell Lung 903Prostatic Neoplasms 595Neoplasm Metastasis 529Leukemia, Myeloid, Acute 514Colorectal Neoplasms 492Lung Neoplasms 490Melanoma 488Multiple Myeloma 478Pancreatic Neoplasms 387Lymphoma 370Ovarian Neoplasms 368Recurrence 365Lymphoma, Non-Hodgkin 348Leukemia 340Leukemia, Lymphocytic, Chronic, B-Cell 322Precursor Cell Lymphoblastic Leukemia-Lymphoma 291Head and Neck Neoplasms 276Carcinoma, Renal Cell 276Brain Neoplasms 276Carcinoma, Hepatocellular 261Glioblastoma 250Myelodysplastic Syndromes 244Lymphoma, Large B-Cell, Diffuse 244Squamous Cell Carcinoma of Head and Neck 241Lymphoma, Follicular 236Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Chemotherapy-induced Neutropenia × Clear all
NCT03559387 2019-02-12

Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

Prolong Pharmaceuticals

Phase 2 Terminated
9 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡